NHS England has announced the five centres that have been awarded the status of Innovation Test Beds in which new approaches to healthcare provision will be assessed and adopted and two centres for the adoption of the Internet of Things (IoT) in healthcare.
Aseptika is pleased to announce that it is one of the innovators partnering with the Test Bed programme in Sheffield for the trial and integration of its Activ8rlives solution for patients with respiratory disease into the new pathways of care.
Test Beds are a new collaborations between the NHS and innovators like Aseptika, which aim to harness technology to address some of the most complex and challenging issues facing patients and the health service.
Successful innovations will then be available for other parts of the NHS to adopt and adapt to the particular needs of their local populations.
The ‘Perfect Patient Pathway’, as the Sheffield City region Test Bed will be known, aims to create the ‘perfect patient pathway’ to bring substantial benefits for patients suffering from long term health conditions, such as diabetes, mental health problems, respiratory diseases, hypertension and other chronic conditions.
About Sheffield Teaching Hospitals NHS Foundation Trust
View the Media Release about Sheffield’s Perfect Patient Pathway test bed by following this link.
About Aseptika Limited (Activ8rlives):
Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by consumers and their healthcare service providers to better self-manage long-term health conditions (LTHC) through self-monitoring.
The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do.
Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.
The Company gained a patent in 2013 protecting the invention of a test for biomarkers of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient.
Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME”eHealth solution 2014developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission.
Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 and won the AXA PPP Health Tech & You Awards. Winner of the Discovery Start-up 2014 Competition run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014. Named on Global Digital Health 100 2014, reflecting the importance of mobile and digital solutions.
Wearable Technology Awards 2015 shortlisted Aseptika in three categories: Best Medical Device (placed third), Best Innovation and Overall Wearable Winner.
Aseptika was granted a patent in the United States and New Zealand protecting its invention for a test for respiratory infections early in 2015.
Aseptika was short-listed as one of twenty semi-finalists for the Cisco British Innovation Gateway (BIG) Awards and was also awarded winner of the Innovation Award for BuddyWOTCH at the Hunts Post Business Awards for 2015.
The Global Digital Health 100 List for 2015 has been named Aseptika Ltd (Activ8rlives) in the list of 100 companies for the second year in a row.
For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com
Activ8rlives, Activ8rlives.com, BuddyWOTCH and EyKos are trademarks of Aseptika Ltd.
For press information, please contact:
Jessica Auton, Marketing Director,
Direct +44 (0)1480 352 821
Mobile +44 (0)7455 922 122